Linked Life Data

18297531

Source:http://linkedlifedata.com/resource/pubmed/id/18297531

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18297531rdf:typepubmed:Citationlld:pubmed
pubmed-article:18297531lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0005768lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0038250lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0023473lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0376152lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0010802lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0242485lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0005791lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C1977882lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C1516698lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C1514468lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0205197lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0392762lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:18297531lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:18297531pubmed:issue3lld:pubmed
pubmed-article:18297531pubmed:dateCreated2008-2-25lld:pubmed
pubmed-article:18297531pubmed:abstractTextImatinib mesylate is the initial therapy of choice for chronic myeloid leukemia in chronic phase (CML-CP), but in some patients, the disease becomes resistant to imatinib. Autologous stem cell transplantation using cells collected while in complete cytogenetic response (CCyR) may represent a therapeutic option for these patients. We mobilized and collected autologous CD34(+) stem cells from 20 CML-CP patients in CCyR, 19 of whom were taking imatinib, and measured BCR-ABL expression in the apheresis products, blood and bone marrow using real-time quantitative PCR (RQ-PCR). Stem cells were mobilized with G-CSF 10 microg/kg daily for 5 days. In patients whose initial collection was <2x10(6) CD34(+) cells/kg, G-CSF dose was increased to 10 microg/kg twice daily on the second attempt, and imatinib was held for 14 days if a third attempt was necessary. All 20 patients successfully mobilized the target yield of 2 to 5x10(6) CD34(+) cells/kg; 16 reached target yield with the first mobilization. The median number of CD34(+) cells collected was 4.4 (range, 2.0 - 8.4)x10(6)/kg in a median of 3 (range, 2 - 6) apheresis days. Of 17 patients whose stem cell products were evaluable by RQ-PCR, 11 (65%) had >or=1 daily product with undetectable BCR-ABL; 4 of these (24%) had no detectable BCR-ABL in any apheresis products. BCR-ABL expression in apheresis products was correlated with levels of expression in the blood and marrow prior to mobilization. No patient has yet required transplantation. With median follow-up of 18 months, all patients remain in CCyR and 9 of 16 (54%) have undetectable BCR-ABL in the most recent blood and marrow sample.lld:pubmed
pubmed-article:18297531pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18297531pubmed:languageenglld:pubmed
pubmed-article:18297531pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18297531pubmed:citationSubsetIMlld:pubmed
pubmed-article:18297531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18297531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18297531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18297531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18297531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18297531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18297531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18297531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18297531pubmed:statusMEDLINElld:pubmed
pubmed-article:18297531pubmed:monthMarlld:pubmed
pubmed-article:18297531pubmed:issn1029-2403lld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:WickremaAmitt...lld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:KarrisonTheod...lld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:LarsonRichard...lld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:ThirmanMichae...lld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:ZhangYanmingYlld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:StockWendyWlld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:KebriaeiParto...lld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:RichElizabeth...lld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:ArtzAndrewAlld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:OdenikeOlatoy...lld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:ChuangKarenKlld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:SherDorieDlld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:GodleyLucyLlld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:GordonMelinda...lld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:McDonnellDian...lld:pubmed
pubmed-article:18297531pubmed:authorpubmed-author:MichaelisLaur...lld:pubmed
pubmed-article:18297531pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18297531pubmed:volume49lld:pubmed
pubmed-article:18297531pubmed:ownerNLMlld:pubmed
pubmed-article:18297531pubmed:authorsCompleteYlld:pubmed
pubmed-article:18297531pubmed:pagination531-7lld:pubmed
pubmed-article:18297531pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:meshHeadingpubmed-meshheading:18297531...lld:pubmed
pubmed-article:18297531pubmed:year2008lld:pubmed
pubmed-article:18297531pubmed:articleTitleSuccessful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.lld:pubmed
pubmed-article:18297531pubmed:affiliationSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.lld:pubmed
pubmed-article:18297531pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18297531pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18297531pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed